Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Shareholder Alert: The Ademi Firm investigates whether Generation Bio Co. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE , Dec. 15, 2025 /PRNewswire/ -- The Ademi Firm is investigating Generation Bio (Nasdaq: GBIO) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with XOMA Royalty Corporation. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

GBIO Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Generation Bio Co. is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Generation Bio Co. (NASDAQ: GBIO) to XOMA Royalty Corporation for $4.2913 per share and one non-transferable contingent value right per share entitling holders to receive potential payments under certain conditions is fair to Generation Bio shareholders. Halper Sadeh encourages Generation Bio shareholders to click here to learn more about their legal rights and options or contact Danie.

XOMA Royalty Enters into Agreement to Acquire Generation Bio

- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna -

Generation Bio Announces Third Quarter 2025 Financial Results

CAMBRIDGE, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company, today reported third quarter financial results.